2024
Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design
Al-Karaghouli M, Ventura-Cots M, Wong Y, Genesca J, Bosques F, Brown R, Mathurin P, Louvet A, Shawcross D, Vargas V, Verna E, Schnabl B, Caballeria J, Shah V, Kamath P, Lucey M, Garcia-Tsao G, Bataller R, Abraldes J. Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design. Hepatology Communications 2024, 8: e0495. PMID: 39082963, DOI: 10.1097/hc9.0000000000000495.Peer-Reviewed Original ResearchConceptsAlcohol-associated hepatitisTrial designRandomized controlled trialsShort-term mortalityInclusion criteriaPredictive valuePrognostic valueControlled trialsShort-term benefitsEfficient trial designTrial outcomesAssociated with significant mortalityCourse of AHCohort of patientsTreatment decisionsSample sizeOrdinal outcomesMortalityOrdinal scaleMELD valuesLandmark analysisTransplant allocationTrialsOutcomesTransplantation
2023
Liver Transplantation for Mahvash Disease, an Inborn Error of Metabolism
Mistry P, Garcia-Tsao G. Liver Transplantation for Mahvash Disease, an Inborn Error of Metabolism. New England Journal Of Medicine 2023, 389: 2010-2013. PMID: 37991861, DOI: 10.1056/nejme2310332.Peer-Reviewed Original Research
2022
Association of serum metabolites and gut microbiota at hospital admission with nosocomial infection development in patients with cirrhosis
Bajaj JS, Reddy KR, Tandon P, Garcia‐Tsao G, Kamath PS, O'Leary JG, Wong F, Lai J, Vargas H, Thuluvath PJ, Subramanian RM, Pena‐Rodriguez M, Sikaroodi M, Thacker LR, Gillevet PM. Association of serum metabolites and gut microbiota at hospital admission with nosocomial infection development in patients with cirrhosis. Liver Transplantation 2022, 28: 1831-1840. PMID: 36017804, PMCID: PMC11097235, DOI: 10.1002/lt.26552.Peer-Reviewed Original ResearchMeSH KeywordsCross InfectionEnd Stage Liver DiseaseFibrosisGastrointestinal MicrobiomeHospitalsHumansLiver CirrhosisLiver TransplantationSeverity of Illness IndexConceptsNosocomial infectionsGut microbiotaAnalysis of covariancePoor outcomeClinical variablesSerum metabolitesCommensal microbiotaNI developmentIntensive care unit transferHigh MELD scoreLiquid chromatography-mass spectrometry metabolomicsSpontaneous bacterial peritonitisCommon nosocomial infectionAdmission WBCHospital courseInpatient outcomesMELD scoreBacterial peritonitisHospital admissionOrgan failureStool microbiotaSerum metabolomicsStool samplesCirrhosisPatients
2021
The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol‐Associated Hepatitis
Musto JA, Eickhoff J, Ventura‐Cots M, Abraldes JG, Bosques‐Padilla F, Verna EC, Brown RS, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Mathurin P, Garcia‐Tsao G, Schnabl B, Bataller R, Lucey MR. The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol‐Associated Hepatitis. Liver Transplantation 2021, 27: 1382-1391. PMID: 34109723, PMCID: PMC11075741, DOI: 10.1002/lt.26203.Peer-Reviewed Original ResearchConceptsAlcohol-associated hepatitisAUDIT-C scoresMELD-NaAUDIT-10Recent alcohol consumptionAlcohol consumptionLiver injuryLiver diseaseSurvival statusAUDIT-ConsumptionEnd-stage liver diseaseAUDIT scoresAlcohol‐Associated HepatitisProspective international databaseMELD-Na scoreAlcohol Use Disorders Identification TestShort-term mortalityShort-term outcomesPrior yearDisorders Identification TestSeverity of drinkingPresenting featuresPrimary outcomeClinical outcomesClinical severityCirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVID‐19: A Multicenter Cohort
Bajaj JS, Garcia‐Tsao G, Wong F, Biggins SW, Kamath PS, McGeorge S, Chew M, Pearson M, Shaw J, Kalluri A, Fagan A, Olofson A, Moini M, de la Rosa Rodriguez R, Reddy KR. Cirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVID‐19: A Multicenter Cohort. Liver Transplantation 2021, 27: 1343-1347. PMID: 33427401, PMCID: PMC8014819, DOI: 10.1002/lt.25981.Peer-Reviewed Original Research
2019
Reply
Wong F, Reddy KR, O’Leary J, Garcia‐Tsao G, Kamath PS, Bajaj JS, for the Study of the Liver F. Reply. Liver Transplantation 2019, 25: 1586-1587. PMID: 31344749, DOI: 10.1002/lt.25612.Commentaries, Editorials and LettersImpact of Chronic Kidney Disease on Outcomes in Cirrhosis
Wong F, Reddy K, O’Leary J, Tandon P, Biggins SW, Garcia‐Tsao G, Maliakkal BJ, Lai JC, Fallon MB, Vargas HE, Subramanian R, Thuluvath PJ, Kamath PS, Thacker L, Bajaj JS. Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. Liver Transplantation 2019, 25: 870-880. PMID: 30908855, PMCID: PMC11075743, DOI: 10.1002/lt.25454.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseKidney diseasePrevalence of CKDEnd-stage liver diseaseHospital clinical courseAcute kidney injuryChild-Pugh scoreChronic liver failureHigher serum creatinineGlomerular filtration rateHigh-risk groupNorth American ConsortiumCKD groupHospital courseKidney injuryRefractory ascitesNegative patientsOverall survivalPositive patientsSerum creatinineCirrhosis etiologyClinical courseHospital admissionHospitalized patientsLiver failureOutcomes After Listing for Liver Transplant in Patients With Acute‐on‐Chronic Liver Failure: The Multicenter North American Consortium for the Study of End‐Stage Liver Disease Experience
O’Leary J, Bajaj JS, Tandon P, Biggins SW, Wong F, Kamath PS, Garcia‐Tsao G, Maliakkal B, Lai J, Fallon M, Vargas HE, Thuluvath P, Subramanian R, Thacker LR, Reddy K. Outcomes After Listing for Liver Transplant in Patients With Acute‐on‐Chronic Liver Failure: The Multicenter North American Consortium for the Study of End‐Stage Liver Disease Experience. Liver Transplantation 2019, 25: 571-579. PMID: 30724010, PMCID: PMC11075742, DOI: 10.1002/lt.25426.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAcute-On-Chronic Liver FailureAdultDisease ProgressionEnd Stage Liver DiseaseFemaleHospital MortalityHospitalizationHumansLiver CirrhosisLiver TransplantationMaleMiddle AgedNorth AmericaProspective StudiesRenal DialysisSeverity of Illness IndexSurvival RateTime-to-TreatmentWaiting ListsConceptsChronic liver failureLiver transplantationNorth American ConsortiumLiver failureEnd-stage liver disease (MELD) scoreEnd-stage liver diseaseAmerican ConsortiumExtrahepatic organ failureAcute kidney injuryLiver Disease scoreOutcomes of patientsPost-LT survivalPerioperative dialysisRenal recoveryKidney injuryLiver transplantOrgan failureLiver diseaseMedian timeMedian MELDACLFSimilar survivalDisease experienceDisease scorePatients
2016
AISF position paper on liver transplantation and pregnancy Women in Hepatology Group, Italian Association for the Study of the Liver (AISF)
Alisi A, Balsano C, Bernabucci V, Berzigotti A, Brunetto M, Bugianesi E, Burra P, Calvaruso V, Cariani E, Coco B, Colle I, Critelli R, De Martin E, Del Buono M, Fabregat I, Faillaci F, Fattovich G, Floreani A, Garcia-Tsao G, Housset C, Karampatou A, Lei B, Mangia A, Martinez-Chantar M, Milosa F, Morisco F, Nasta P, Ozben T, Pollicino T, Ponti M, Pontisso P, Reeves H, Rendina M, Rodríguez-Castro K, Sagnelli C, Sebastiani G, Smedile A, Taliani G, Vandelli C, Vanni E, Villa E, Vukotic R, Zignego A, Burra P, Rodríguez-Castro K, Guarino M, Morisco F, Villa E, Mazzella G. AISF position paper on liver transplantation and pregnancy Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). Digestive And Liver Disease 2016, 48: 860-868. PMID: 27267817, DOI: 10.1016/j.dld.2016.04.009.Commentaries, Editorials and LettersConceptsLiver transplant recipientsTransplant recipientsLiver transplantationReproductive ageFemale liver transplant recipientsHypertension/preeclampsiaFoetal growth restrictionFirst successful pregnancyLive birth rateManagement of pregnancyIssue of pregnancyGestational diabetesLiver transplantPreterm deliveryPregnancy outcomesTransplant hepatologistsPediatric patientsSuch patientsPregnancy womenSuccessful pregnancyIncreased incidenceItalian recommendationsSexual functionGrowth restrictionHigh-risk ones
2015
High risk of delisting or death in liver transplant candidates following infections: Results from the North American consortium for the study of end‐stage liver disease
Reddy KR, O'Leary JG, Kamath PS, Fallon MB, Biggins SW, Wong F, Patton HM, Garcia‐Tsao G, Subramanian RM, Thacker LR, Bajaj JS, Disease F. High risk of delisting or death in liver transplant candidates following infections: Results from the North American consortium for the study of end‐stage liver disease. Liver Transplantation 2015, 21: 881-888. PMID: 25845966, DOI: 10.1002/lt.24139.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseLiver transplantationOrgan failureNorth American ConsortiumLiver diseaseUnderwent transplantationMELD scoreMedian ageEnd-stage liver disease (MELD) scoreTertiary-care hepatology centersAmerican ConsortiumExtrahepatic organ failureMean MELD scoreLiver Disease scoreLiver transplant candidatesPatients' median ageHepatitis C virusType of infectionPrevention of infectionHepatology centersTransplant candidatesCirculatory failureC virusInfected patientsHigh risk
2011
Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1*
Boyer TD, Sanyal AJ, Garcia‐Tsao G, Regenstein F, Rossaro L, Appenrodt B, Gülberg V, Sigal S, Bexon AS, Teuber P, Group T. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1*. Liver Transplantation 2011, 17: 1328-1332. PMID: 21837734, PMCID: PMC3760727, DOI: 10.1002/lt.22395.Peer-Reviewed Original ResearchMeSH KeywordsAlbuminsCohort StudiesHepatorenal SyndromeHumansLiver FailureLiver TransplantationLypressinPrognosisSurvival RateTerlipressinVasoconstrictor AgentsConceptsHepatorenal syndrome type 1Liver transplantationHepatorenal syndromeSyndrome type 1Nontransplant patientsTransplant patientsSurvival benefitSurvival rateType 1Pretransplant renal functionUse of terlipressinClear survival benefitCohort of patientsSurvival of patientsHRS reversalPosttransplant managementLiver transplantPosttransplant survivalMost patientsPosttransplant outcomesRenal functionPoor prognosisTerlipressinPatientsTransplantation
2010
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis
Salerno F, Guevara M, Bernardi M, Moreau R, Wong F, Angeli P, Garcia‐Tsao G, Lee SS. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver International 2010, 30: 937-947. PMID: 20492521, DOI: 10.1111/j.1478-3231.2010.02272.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCirrhotic patientsHepatorenal syndrome type 2Transjugular intrahepatic portosystemic shuntEpisode of ascitesChronic renal insufficiencyLow sodium dietStandard medical treatmentIntrahepatic portosystemic shuntOccurrence of refractorinessCentral hypovolaemiaVasoconstrictor systemsArterial hypotensionDiuretic dosesLiver transplantationPortal hypertensionRefractory ascitesRenal insufficiencySodium dietSystemic haemodynamicsFrequent complicationSevere complicationsSerious complicationsSuch patientsPortosystemic shuntRenal sodium
2008
Vascular disorders of the liver
DeLeve LD, Valla D, Garcia‐Tsao G. Vascular disorders of the liver. Hepatology 2008, 49: 1729-1764. PMID: 19399912, PMCID: PMC6697263, DOI: 10.1002/hep.22772.ChaptersAcute kidney injury in cirrhosis
Garcia‐Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008, 48: 2064-2077. PMID: 19003880, DOI: 10.1002/hep.22605.Peer-Reviewed Original ResearchConceptsAcute kidney injuryAcute renal failureHepatorenal syndromeKidney injurySerum creatinineSpecific therapyEffective arterial blood volumeUseful bridging therapyAcute tubular necrosisRenal blood flowSpontaneous bacterial peritonitisArterial blood volumeBridging therapyLiver transplantationPrerenal azotemiaRenal dysfunctionRenal failureTubular necrosisBacterial peritonitisVasodilatory stateRelative hypovolemiaVolume repletionCommon causeCirrhosisBlood flow
2006
Model for end‐stage liver disease (MELD) exception for hereditary hemorrhagic telangiectasia
Garcia‐Tsao G, Gish RG, Punch J. Model for end‐stage liver disease (MELD) exception for hereditary hemorrhagic telangiectasia. Liver Transplantation 2006, 12: s108-s109. PMID: 17123286, DOI: 10.1002/lt.20978.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsLiver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations
Buscarini E, Plauchu H, Tsao G, White RI, Sabbà C, Miller F, Saurin JC, Pelage JP, Lesca G, Marion MJ, Perna A, Faughnan ME. Liver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations. Liver International 2006, 26: 1040-1046. PMID: 17032403, DOI: 10.1111/j.1478-3231.2006.01340.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHereditary hemorrhagic telangiectasiaLiver involvementHemorrhagic telangiectasiaIntensive medical therapyFormal consensus development processMinority of patientsFirst-line imagingFocal nodular hyperplasiaConsensus development processHHT populationLiver biopsyMedical therapyClinical managementNodular hyperplasiaConsensus statementConsensus recommendationsInvasive therapyDoppler USGeneral populationNominal group techniquePatientsTherapeutic issuesMedian scoreTherapyInvolvement